Full history for every metric is available with a Kvantra account
Provention Bio, Inc. (PRVB)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 1 | 13 | 13 |
| Operating profit | $m | -128 | -128 | |||||
| Net profit | $m | -9 | -26 | -42 | -99 | -114 | -114 | -113 |
| EPS reported | $ | -1.52 | -1.60 | |||||
| Operating cashflow per share | $ | -1.01 | -1.01 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -1.02 | -1.02 | |||||
| Free cash flow | $m | -76 | -76 | |||||
| Net debt | $m | -141 | -142 | |||||
| Book value equity | $m | 122 | 122 | |||||
| Book value per share | $ | 1.63 | 1.63 | |||||
| Number of shares | m | 74.72 | 74.72 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 6.48 | 19.49 | |||||
| P/S LTM | x | 61.25 | 184.21 | |||||
| P/FCF LTM | x | -10.36 | -31.17 | |||||
| EV/EBITDA LTM | x | -6.17 | -17.93 | |||||
| EV/Sales LTM | x | 59.69 | 173.24 | |||||
| Earnings Yield LTM | % | -14.38% | -6.08% | |||||
| FCF Yield | % | -9.65% | -3.21% | |||||
| Quality | ||||||||
| ROE | % | -93.20% | 133.43% | |||||
| ROIC | % | -78.27% | -78.27% | |||||
| Operating margin | % | -993.88% | -993.88% | |||||
| Gross margin | % | 96.03% | 96.03% | |||||
| FCF/Sales | % | -590.95% | -590.95% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +824.37% | +824.37% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.19 | -3.19 | |||||
| Net Debt/EBITDA | x | 0.16 | 0.16 | |||||
| EBIT/Net interest | x | -123.59 | -123.59 | |||||
| Net debt/market cap | % | -17.86% | -5.96% | |||||
| Net debt/Equity | x | -1.16 | -1.16 | |||||
| Gross debt/equity | x | 0.20 | 0.20 | |||||
Company overview
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Provention Bio, Inc. (PRVB)
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free